Drug - target binding and Ligand Binding Assays (LBA)
Drug - target binding and Ligand-binding assays (LBA) are commonly used within the scope of Pharmacodynamic (PD) assessments to quantify the binding affinity of biologics to their respective protein targets. In addition, Ligand-binding assays are key tools for Pharmacokinetic (PK) / Toxicokinetic (TK) evaluations and the assessment of Immunogenicity of biologic drugs. IBR Inc. is experienced in development, validation and operation of ligand-binding assays in compliance with the GxP quality standards. IBR Inc. supports your projects from pre-clinical to clinical development.
Drug - target binding and Ligand Binding Assay Technologies
With its state-of-the-art technology platforms, IBR Inc. provides a broad spectrum of cell-based or non cell-based ligand-binding assays.
IBR Inc.'s experienced scientists advise you on selecting the most suitable assay format to ensure robust and reliable data.
Flow Cytometry is the method of choice for detection ligand-binding interactions on the cell-surface.
IBR Inc.'s advanced Immuno-Assay Technologies are designed for increased sample throughput and combine minimal samples volumes with highest sensitivity at retained robustness.
IBR Inc.'s multimode Microplate Readers allow for classical detection of ligand-binding interactions by measurement of absorbance and fluorescence.
For Ligand Binding Assays that require very high sensitivity IBR Inc. leverages
- TRF (Time-Resolved Fluorescence), including Delfia
- TR-FRET (Time-resolved fluorescence energy transfer), including HTRF (homogenous TRF) cell-based assays and Lance
In addition, IBR Inc. provides classical ELISA and ELISpot.
Submit a Question or Request
Simply fill out the form below and a member of our team will follow up with you shortly.